Skip to main content
Equibles

Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP

Board Member

Bicycle Therapeutics PLC (BCYC)

Equibles does not estimate personal net worth.

Get an email with a short summary when Bicycle Therapeutics PLC publishes a filing, an earnings call transcript or a press release.

Get BCYC alerts

About Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP

Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP is recorded as Board Member at Bicycle Therapeutics PLC (BCYC) since August 12, 2025. Bicycle Therapeutics PLC reported in an 8-K filed August 20, 2026 that Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP resigned as Class II director of the Board of Directors, effective August 18, 2026. Bicycle Therapeutics PLC reported in an 8-K filed August 8, 2025 that Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP was appointed Director, effective August 12, 2025. Bicycle Therapeutics PLC is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Bicycle Therapeutics PLC includes Kevin Lee (CEO and Board Member), Felix J. Baker, Ph.D. (Chairman and Board Member), Pierre Legault (Chairman) and 7 others.

“On August 18, 2026, Charles Swanton resigned as a Class II director of the Board of Directors (the “Board”) of Bicycle Therapeutics plc (the “Company”), as a member of the Board’s committees and as a member of the Company’s Clinical Advisory Board, effective immediately.”
Bicycle Therapeutics PLC Form 8-K, filed August 20, 2026 · Read the filing
“On August 6, 2025, the Company’s Board of Directors (the “Board”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Charles Swanton, M.D., Ph.D., FRS, FMedSci, FRCP, to the Board and the Scientific Committee of the Board, effective as of August 12, 2025, New York City time.”
Bicycle Therapeutics PLC Form 8-K, filed August 8, 2025 · Read the filing

Affiliation history

Company network

Leadership on record at Bicycle Therapeutics PLC

Recent activity